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basis of long QT syndrome (LQTS) have led to signiﬁcant changes in
the diagnosis and management of this life-threatening condition.
Genetic and electrocardiogram (ECG) tests are the most relevant
examples among testing strategies for LQTS, yet their cost-
effectiveness remains controversial. Objective: The aim of this work
was to review the available evidence on the cost-effectiveness of
genetic and ECG testing strategies for the diagnosis of LQTS.Methods:
We performed a systematic review of the literature on the cost-
effectiveness of genetic and ECG screening strategies for the early
detection of LQTS using MEDLINE, EMBASE, and CRD databases
between 2000 and 2013. A weighted version of Drummond checklist
was instrumental in further assessing the quality of the included
studies. Results: We identiﬁed four eligible articles. Among them,
genetic testing in the early detection of LQTS was cost-effective
compared with no testing in symptomatic cases and not cost-ee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.03.1788
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ndence to: Fernando Matias Gonzalez, Bocconi Uneffective when compared with watchful waiting in asymptomatic
ﬁrst-degree relatives of patients with established LQTS although it
reached cost-effectiveness in higher risk subgroups, whereas ECG
testing in neonates was highly cost-effective when compared with
any screening strategy. Conclusions: LQTS proﬁling and patients’
stratiﬁcation have the potential to improve the disease management.
Because of the limited current knowledge in this ﬁeld, the present
review recommends to perform further cost-effectiveness evaluations
of the genetic and ECG screening alternatives, especially within
European health care systems, which are still not available in the
literature on genetic testing.
Keywords: cost-effectiveness, ECG, economic evaluation, genetic
testing, long QT syndrome.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Long QT syndrome (LQTS) is a genetic disorder characterized by a
prolonged ventricular repolarization (prolonged QT interval) that
is associated with syncope and sudden death [1–5]. LQTS is
considered to be responsible for as many as 2000 to 3000
unexpected or sudden deaths in children and young adults in
the United States each year [4]. Disease prevalence is approx-
imately 1 in 2000, with a higher impact in sudden death
syndrome [5]. It is estimated that almost 10% of the sudden
infant death syndrome cases may be attributable to mutations in
LQTS-related genes, and 25% to 35% of the cases of sudden
cardiac death in the young to either LQTS or catecholaminergic
polymorphic ventricular tachycardia genes [4,6].
Literature distinguishes among 13 LQTS subtypes (LQT1, LQT2,
LQT3 and up to LQT13), with the ﬁrst three subtypes accounting
for the vast majority of cases. LQT1, LQT2, and LQT3 are caused
by mutations in KCNQ1, KCNH2, and SCN5A genes, respectively,
each encoding a cardiac ion channel that is important for
ventricular repolarization. These LQTS subtypes are typicallyassociated with particular symptoms; however, symptoms asso-
ciated with one subtype are sometimes also seen in patients with
other forms of LQTS. For all forms of LQTS, the risks of experi-
encing cardiac events are higher if the rate-corrected QT interval
is greater than 500 milliseconds.
To determine the LQTS subtype, genetic tests are performed in
blood, saliva, or tissue of tested individuals [4]. Electrocardiogram
(ECG) is used in the detection of prolonged QT interval, and it has
recently been identiﬁed that T-wave morphology can help in
speciﬁcally proﬁling some limited number of LQTS subtypes [7,8].
The potential lethality of LQTS, combined with recent aug-
mented biological understanding and technological improve-
ments varying its management, underlies the public health
concern for the topic. Given that genetic testing options often
reach the market with less cost-effectiveness scrutiny than do
pharmaceuticals or other medical technologies, the public health
concern is higher. Moreover, the LQTS genotype is reported to
have diagnosis and also prognosis and practical value, thus an
increased potential within clinical decision making [9]. The
evolving role of genetic testing within clinical decision makingociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 0 0 – 7 0 8 701was noted by American and European practice guidelines [10],
though the subject is a matter of some controversy.
At the moment, optimal screening strategies are missed and
standardized methodologies are needed, thus enforcing the
attention on LQTS testing cost-effectiveness estimations.
The present review aimed to evaluate the cost-effectiveness
evidence supporting different screening alternatives for LQTS,
through the collection and the assessment of economic evalua-
tion studies regarding genetic and ECG testing alternatives in
infants and young adults at risk of LQTS. This information may
be useful to policymakers at different levels and in different
health care settings, and could provide a base for future updates
as new research and information becomes available. To contrib-
ute to this process, some areas of uncertainty in cost-
effectiveness evaluations of LQTS testing are also identiﬁed and
discussed.Methods
The systematic literature review was conducted in accordance
with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [11] to examine the economic
evidence supporting LQTS screening strategies. Studies were
identiﬁed through a systematic literature search in MEDLINE,
EMBASE, and CRD databases. The literature search included
publications in English language from January 2000 to December
2013. The following key words were used and combined to search
the databases: 1) [(long QT syndrome OR LQTS OR long-QT
syndrome OR long QTS OR channelopathies OR inherited
arrhythmias OR arrhythmias); 2) [*genetic AND (testing OR test
OR screening OR CGT) OR electrocardiogram OR ECG); and 3)
[(*economic evaluation OR health technology assessment) OR
[*cost AND (effectiveness OR beneﬁt OR utility OR consequence)].
Last, 1), 2), and 3) were connected with AND. Relevant articles
were examined by two independent authors (F.M.G. and A.P.)
who screened 1) the titles, 2) the abstracts, and 3) the full texts. At
each stage, the selection of articles was cross-checked by the two
authors. Where uncertainty or disagreement regarding the inclu-
sion was present, the inclusion or exclusion of the article
concerned was discussed until agreement was reached.
Selection of studies was based on the following inclusion
criteria:1. Original full economic evaluations that compare alternative
LQTS strategies;2. Genetic or ECG screening for LQTS; and
3. Exclusion of studies focused on sudden cardiac death syn-
drome screening programs that do not provide disaggregate
cost-effectiveness ratios for LQTS screening.
In addition, a weighted version of the Drummond checklist
was used to further assess the quality of the selected studies [12].
The checklist is speciﬁc for the assessment of economic evalua-
tion studies, and it is divided into three main sections: study
design, data collection, and the analysis and interpretation of
results. The list consists of 35 items, which were examined by
two independent authors (F.M.G. and A.P.) for the included stu-
dies. The weighted version was used in previous studies [12-14]
and assigns a maximum global score of 119 (maximum scores of
26 for study design, 48 for analysis and interpretation of results,
and 45 for data collection).Results
The primary literature search retrieved 454 potentially relevant
articles. After removing duplicate citations, 439 referencesremained for screening. Title and abstract screening excluded
398 and 35 articles, respectively. After applying the predeﬁned
full-text eligibility criteria to the remaining 41 references, and
adding 1 reference retrieved through manual screening of
selected studies’ bibliography, four relevant articles were
included (Fig. 1).
The four included studies vary in terms of perspectives,
country settings, and assumptions. A summary of selected
characteristics of the included cost-effectiveness studies is
reported in Table 1.
The cost-effectiveness of ECG universal screening and target-
ing selected groups in comparison to no screening was analyzed
in two [15,16] of the four studies. Both reports examine neonatal
testing strategies and trade-offs, and their ﬁnal estimations
support the cost-effectiveness of screening though with different
scopes dependent on the estimation of key variables and health
systems characteristics. However, cost-effectiveness analyses
performed by Perez et al. [5] and Phillips et al. [17] incorporate
genetic testing as their main focus, increasing the spectrum of
testing alternatives and strategies in the system. In the latter
studies, the population targets will be ampliﬁed beyond neonates
including the assessment of testing diagnosed LQTS cases’ family
members.
Zupancic et al. [15] conducted a cost-effectiveness analysis
comparing ECG universal screening and high-risk screening to no
screening in neonates (day 3 after birth). The model was built on
three scenarios regarding the pathophysiological dynamics and
association between LQTS and sudden infant death syndrome.
The study was performed by developing a decision tree for the
ﬁrst year, combined with a Markov model after 1 year over a time
horizon of 74 years. The base-case results showed an incremental
cost-effectiveness ratio (ICER) of $3.403/life-year gained ($2000) in
high-risk screening and of $18.465/life-year gained ($2000) in
universal screening scenario. Both results were particularly
dependent on the effectiveness of therapy over sudden infant
death syndrome. The study results were robust as conﬁrmed by
univariate sensitivity analyses performed on the most critical
parameters.
Quaglini et al. [16] performed a cost-effectiveness analysis
from the Italian National Health Service perspective in which
routine mass screening was compared with no screening strat-
egy. Effectiveness estimates were mainly based on a prospective
ECG study in 30,000 infants. Two analyses were performed: a
primary analysis focused on LQTS alone and a secondary analysis
focused also on congenital heart diseases. The cost-effectiveness
analysis was performed through a decision analytic model in
which a decision tree was combined with a Markov model. The
base-case results showed that the ICER was €11.740/life-year
saved (€2005). The secondary analysis was more cost-effective,
leading to an ICER of €7.022/life-year saved. As conﬁrmed by the
probabilistic sensitivity analysis, the base-case results were
robust.
Phillips et al. [17] analyzed the cost-effectiveness of genetic
testing as compared to no testing for symptomatic index cases
(aged 15–40 years) with deﬁnite or inconclusive Schwartz and
Moss clinical score. The model assessed the cost-effectiveness of
testing the three most common mutation subtypes of LQTS for
this target population. The analysis was ended at the age of 40
years because less is known about LQTS after this age. A decision
tree model was developed, and effectiveness data were based on
the literature. The base-case results showed that the ICER was
$2.500/life-year saved ($2005), hence deemed highly cost-effec-
tive, as conﬁrmed by the sensitivity analysis. The main beneﬁt
from testing was a high accuracy in diagnosing and treating
individuals. Indeed, implantable cardioverter-deﬁbrillator im-
plants could be avoided in 10% of the patients with conclusive
scores because of subtype of mutation or a negative test result;
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Fig. 1 – Flow diagram for databases search. LQTS, Long QT Syndrome.
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traditionally receiving beta-blockers and being restricted from
physical activity could be conﬁrmed as negative cases.
The cost-effectiveness analysis developed by Perez et al. [5]
assessed the cost-effectiveness of genetic testing compared with
1) watchful waiting with treatment after symptoms and 2)
empirical treatment with beta-blockers in asymptomatic 10-
year-old, ﬁrst-degree relatives of a patient with established LQTS
(Schwartz score Z4). Genetic testing included ﬁve subtypes of
genes, and family members were tested for the mutation ﬁrst
identiﬁed in the index case. The hypothetical cohort was fol-
lowed over a time horizon of 60 years. Health care direct costs
were considered. Cost-effectiveness results suggested that
genetic testing was moderately expensive, leading to $67.400
per quality-adjusted life-year (QALY) ($2008) gained compared
with watchful waiting. This result is signiﬁcantly higher than the
acceptable recommended threshold/QALY. The study showed
that the cost-effectiveness of genetic testing reached the
accepted threshold when applied to 1) relatives with a higher
clinical suspicion of LQTS (pretest probability 65%–81%); 2) fam-
ilies with a higher than average risk of sudden death; and 3)
larger families (two or more ﬁrst-degree relatives tested) among
individuals with a higher than average family history of sudden
death from LQTS. Univariate sensitivity analyses highlighted that
model results were highly sensitive to the annual risk of death
and to the pretest probability of LQTS in ﬁrst-degree relatives of
the index case. Results were also sensitive to the probability of
development of symptoms, the effects of beta-blockers on quality
of life, and the efﬁcacy of drug therapy.The quality appraisal performed according to the Drummond
checklist is reported in Table 2.
All the studies achieved a medium to high quality level. In the
section regarding “Study Design,” the research question deﬁnition,
speciﬁcation of its economic relevance, and study viewpoint (items
1–3), the rationale and the description of alternative programs
(items 4 and 5), and the choice and form of economic evaluation
(items 6 and 7) are given. Two of the studies achieved the
maximum score for study design [5,16], whereas in the other two
cases the study viewpoint was not sufﬁciently clearly stated [15,17].
In the section regarding “Data Collection,” a clear statement of
the sources of effectiveness estimates used (item 8), of the
primary outcome measures for the economic evaluation (item
11), of quantities and unit costs and the methods for their
estimation (items 16 and 17), the speciﬁcation on details of any
model used (item 21), and the choice of model key parameters
(item 22) are provided. All the studies observed a medium score
for data collection, with one study [5] scoring higher owing to a
more detailed reporting of patients’ characteristics included in
the analysis. Finally, the section “Analysis and Interpretation of
Results” provides details on time horizon, discount rates (items
22–25), statistical tests, conﬁdence intervals, sensitivity analysis,
alternatives compared, and major outcomes reporting and cav-
eats (items 26–35). All the studies achieved a medium to high
score for analysis and interpretation of results. According to the
Drummond checklist scale used, out of a maximum possible
score of 122, the average quality overall score for the included
studies is 94.5, with a minimum score of 89 and a maximum of
103 (Table 2).
Table 1 – Outcomes summary.
Study Type of
economic
evaluation
Country/
perspective/
time horizon
Sample Intervention Comparator Effectiveness
source
[references]/
evidence
feature
Screening
power
Base-case
results
(expressed in
terms of
ICER)/
incremental
cost (IC)
incremental
effectiveness
(IE)
Price, year/
discount
rate
Sensitivity
analysis
Model
Zupancic
et al.
[15]
CEA USA Hypothetical
cohort of
healthy term
infants
ECG No screening Literature [24–
34]
Sensitivity,
50%
US $3.403/LYG
(1); US
$18.465/LYG
(2)
US $, 2000 Univariate DAM
Not speciﬁc (1) High-risk
screening and
Mainly based
on a large
prospective
cohort study
[34] and case
registries
[28,29]
Speciﬁcity,
98%
3% Decision
tree
75 y (2) Universal
screening
(1) High-risk
screening:
IC: US $4.97;
IE: 0.0015
LYG. (2)
Universal
screening:
IC: US
$85.03; IE:
0.0046 LYG
Markov
model
Quaglini
et al.
[16]
CEA Italy 30,000 infants
(days 15–25) in
the primary
analysis and
50,000 infants in
the secondary
analysis
ECG nationwide
screening
program
No screening Literature
[28,35–46]
False
negative,
20%
€11.740/LYS (1)
€7.022/LYS
(2)
€, 2000 PSA DAM
NHS Prevalence of
LQTS and
neonatal
ECG
screening
data based
on a large
prospective
cohort [37]
3% Monte-Carlo
simulation
Decision
tree and
Lifetime (1) Primary
analysis: IC:
€35.22; IE: 3
LYS. (2)
Secondary
analysis: IC:
€42.13; IE:
0.006 LYS
Markov
model
Phillips
et al.
[17]
CEA USA Individuals aged
15–40 y,
assuming to be
symptomatic
index cases. Use
of literature
parameters and
Mayo Clinic
cohort (n ¼ 541)
Genetic testing No testing Literature
[6,20,35,36,4-
3,47,48]
Not speciﬁc US $2.500/LYS US $, 2005 Univariate DAM
Not speciﬁc IC: US $2.100;
IE: 0.04 LYS
3% Decision
tree
Include data
from Mayo
Clinic Cohort
[20]
continued on next page
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Table 1 – continued
Study Type of
economic
evaluation
Country/
perspective/
time horizon
Sample Intervention Comparator Effectiveness
source
[references]/
evidence
feature
Screening
power
Base-case
results
(expressed in
terms of
ICER)/
incremental
cost (IC)
incremental
effectiveness
(IE)
Price, year/
discount
rate
Sensitivity
analysis
Model
Perez et al.
[5]
CUA, CEA USA Hypothetical
cohort of
asymptomatic
10-y-old, ﬁrst-
degree family
members of a
patient who has
deﬁnite clinical
evidence of
LQTS
Genetic testing
to family
members
(only for the
mutation
identiﬁed in
the index
patient)
(1) Empirical
treatment of
relatives
with beta-
blockers; (2)
Watchful
waiting and
treatment
only after
the
development
of symptoms
Literature
[22,29,35,43,-
45,49–58]
Sensitivity,
90%
US $67.400/
QALY vs.
watchful
waiting;
o50.000/
QALY when
applied to
selected
higher risk
patients
US $, 2008 Univariate DAM
Societal (only
direct
health care
costs
included)
Mainly based
on
prospective
cohort
studies
[29,43,35,51]
Speciﬁcity,
90%
3% Markov
model
70 y IC: US $9.419;
IE: 0.14
QALY
CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DAM, decision analysis model; ECG, electrocardiogram; IC, incremental cost; ICER, incremental cost-effectiveness ratio; IE,
incremental effectiveness; LYG, life-year gained; LQTS, long QT syndrome; LYS, life-year saved; QALY, quality-adjusted life-year; PSA, probabilistic sensitivity analysis.
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Table 2 – Quality assessment of included studies.
Referees’ checklist item Study ID
Zupancic
et al. [15]
Quaglini
et al. [16]
Phillips
et al.
[17]
Perez
et al. [5]
Study design (1) The research question is stated. Y 4 Y 4 Y 4 Y 4
(2) The economic importance of the research question is
stated.
Y 3 Y 3 Y 3 Y 3
(3) The viewpoint(s) of the analysis is clearly stated and
justiﬁed.
NC – Y 4 NC – Y 4
(4) The rationale for choosing the alternative programs
or interventions compared is stated.
Y 4 Y 4 Y 4 Y 4
(5) The alternatives being compared are clearly
described.
Y 4 Y 4 Y 4 Y 4
(6) The form of economic evaluation used is stated (e.g.,
CEA, CUA, and CBA).
Y 4 Y 4 Y 4 Y 4
(7) The choice of form of economic evaluation is
justiﬁed in relation to the questions addressed.
Y 3 Y 3 Y 3 Y 3
Data collection (8) The source(s) of effectiveness estimates used is
stated.
Y 4 Y 4 Y 4 Y 4
(9) Details of the design and results of effectiveness
study are given (if based on a single study).
NA – NA – NA – NA –
(10) Details of the method of synthesis or meta-analysis
of estimates are given (overview).
NA – NA – NA – NA –
(11) The primary outcome measure(s) for the economic
evaluation is clearly stated.
Y 4 Y 4 Y 4 Y 4
(12) Methods to value health states and other beneﬁts
are stated.
NA – NA – NA – Y 4
(13) Details of the subjects from whom valuations were
obtained are given.
N – N – N – Y 4
(14) Productivity changes (if included) are reported
separately.
N – N – N – N –
(15) The relevance of productivity changes to the study
question is discussed.
NA – NA – NA – NA –
(16) Quantities of resources are reported separately
from their unit costs.
Y 3 Y 3 Y 3 Y 3
(17) Methods for the estimation of quantities and unit
costs are described.
Y 4 Y 4 Y 4 Y 4
(18) Currency and price data are recorded. Y 3 Y 3 Y 3 Y 3
(19) Details of currency of price adjustments for
inﬂation or currency conversion are given.
NC – NC – NC – NC –
(20) Details of any model used are given. Y 3 Y 3 Y 3 Y 3
(21) The choice of model used and the key parameters
on which it is based are justiﬁed.
Y 4 Y 4 Y 4 Y 4
Analysis and
interpretation of
results
(22) Time horizon of costs and beneﬁts is stated. Y 4 Y 4 Y 4 Y 4
(23) The discount rate(s) is stated. Y 4 Y 4 Y 4 Y 4
(24) The choice of rate(s) is justiﬁed. N – Y 3 N – Y 3
(25) An explanation is given if costs or beneﬁts are not
discounted.
NA – NA – NA – NA –
(26) Details of statistical tests and conﬁdence intervals
are given for stochastic data.
Y 3 Y 3 Y 3 Y 3
(27) The approach to sensitivity analysis is given. Y 4 Y 4 Y 4 Y 4
(28) The choice of variables for sensitivity analysis is
justiﬁed.
Y 3 Y 3 Y 3 Y 3
(29) The ranges over which the variables are varied are
stated.
Y 3 Y 3 Y 3 Y 3
(30) Relevant alternatives are compared. Y 3 Y 3 Y 3 Y 3
(31) Incremental analysis is reported. Y 3 Y 3 Y 3 Y 3
(32) Major outcomes are presented in a disaggregated as
well as aggregated form.
Y 3 Y 3 Y 3 Y 3
(33) The answer to the study question is given. Y 4 Y 4 Y 4 Y 4
(34) Conclusions follow from the data reported. Y 4 Y 4 Y 4 Y 4
continued on next page
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Table 2 – continued
Referees’ checklist item Study ID
Zupancic
et al. [15]
Quaglini
et al. [16]
Phillips
et al.
[17]
Perez
et al. [5]
(35) Conclusions are accompanied by the appropriate
caveats.
Y 4 Y 4 Y 4 Y 4
Final score 89 96 89 104
CBA, cost-beneﬁt analysis; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; N, not; NA, not appropriate; NC, not clear; Y, yes.
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As integral components of the clinical management pathways
enabling timely and accurate treatment of patients with LQTS,
ECG and genetic screening have the potential to reach cost-
effectiveness under certain circumstances. Assuming a
willingness-to-pay threshold of US $50,000, the results in this
review indicate that ECG screening in neonates is particularly
cost-effective in high-risk groups and remains within cost-
effectiveness thresholds in universal screening scenarios, as
compared with no screening [15,16]. In the case of genetic testing,
a high cost-effectiveness was observed in testing for the three
most common LQTS subtypes in symptomatic index cases (aged
15–40 years) with deﬁnite or inconclusive Schwartz and Moss
clinical score, as compared with no testing [17]. Genetic testing of
asymptomatic ﬁrst-degree relatives of a patient with established
LQTS (Schwartz scoreZ4) provides a more varied picture. In such
a case, genetic testing is not cost-effective as compared to
watchful waiting although it reaches cost-effectiveness when
applied to relatives with a higher clinical suspicion of LQTS
(pretest probability 65%–81%), or to families with a higher
than average risk of sudden death, or to larger families (two or
more ﬁrst-degree relatives tested) among individuals with a
higher than average family history of sudden death from LQTS
[5].
Among the observed cost-effectiveness analyses, some key
drivers and areas of uncertainty were identiﬁed. These could be
classiﬁed into broad categories related to screening costs, genetic
testing characteristics and impact over mortality rates, and
availability of clinical data.
Channelopathies genetic testing costs represent a major
driver for cost-effectiveness. Such tests are covered to different
extents by insurance providers, ranging from full coverage to
denial, with most of them covering 50% to 75% of the costs [6].
This environment supports the need for further data on the cost-
effectiveness of screening strategies within European health
systems, which are still not available in the literature.
Genetic testing probabilities combined with LQTS mortality
rates are evidently at the core of cost-effectiveness estimations.
There is broad consensus on the increased effectiveness and use
of genetic screening as adjunct to clinical and phenotypic assess-
ment in selected higher risk subgroups. Some areas of uncer-
tainty, however, need to be addressed by further research.
Among these, opportunities related to targeted genes versus a
panel of genes testing (risks related to false positives due to
nontargeted exons), the possible role of screening strategies in
disclosing other channelopathies (such as Brugada syndrome,
short QTS, or catecholaminergic polymorphic ventricular tachy-
cardia) [18,-20], LQTS subtypes beyond the most common ones,
compound mutations [20,21], timing of testing and sequencing of
testing, as well as ECG recent use in genotyping. The validity ofthe genetic test has been accounted for only in the Perez et al.
study [5].
Also, differences in frequencies in population ethnicities may
have an impact on cost-effectiveness. Effectiveness data sources
may reﬂect these differences, and evaluations may ﬁnd the need
to take them into account. Ethical considerations might play a
relevant role here regarding rationing of resources [22]. Hetero-
geneity is indeed a ﬁeld for further research to improve the
methodologies accounting for it [23].
Finally, clinical data availability is an area of uncertainty for
cost-effectiveness analyses in LQTS screening. Furthermore,
although such testing strategies are moving toward increased
personalization and efﬁcacy, genetic proﬁling–enhanced efﬁcacy
depends in part on subtypes, mortality risk, and effects of
subsequent treatments. Hence, speciﬁc clinical data on stratiﬁed
patient’s subgroups are needed in the future. Age, sex, and ethnic
subtypes can play different roles in driving key variables. The
relevance of quality-of-life adjustment may deserve further
attention in some cases, as observed in Perez et al. [5].
Our study has several limitations. First, the study is restricted
to English language publications, which may lead to excluding
evidence published in other languages. Second, the number of
studies available is still limited, clearly not allowing a well-
deﬁned conclusion regarding the use of ECG or genetic testing
for LQTS subtypes. Despite rapid advances in technologies and
scientiﬁc understanding of LQTS, few studies have addressed the
cost-effectiveness of existent genetic testing on the subject.
Third, included studies differ with regard to perspectives, country
settings, and assumptions, making comparison more difﬁcult.
Last, the difﬁculty of conducting trials and measuring preferences
for quality-of-life adjustments in relation to the topic impedes a
more robust and comprehensive evidence base enabling full
economic evaluations. Trends in current LQTS screening tech-
nology suggest future demand increase, raising the need for
further speciﬁc clinical information and cost-effectiveness esti-
mation. Both screening strategies improvement and LQTS geno-
typic, phenotypic, and clinical heterogeneity are producing or
fostering such renewed need. Moreover, quantiﬁcation of the
economic implications of stratiﬁed medicine and cost-
effectiveness assessments of LQTS proﬁling has become more
relevant and possible areas for improvement in cost-
effectiveness data availability are present. In particular, the
methods applied in cost-effectiveness evaluations, the target
groups analyzed, and the levels of evidence to support clinical
effectiveness are some of the topics in need of further analysis.
Special attention is drawn over the necessity for cost-
effectiveness data of LQTS genetic screening in European health
systems, which are still not available in the literature. An
important aspect that should be further investigated is repre-
sented by the indirect costs due to LQTS.
Source of ﬁnancial support: The systematic review has been
carried out without any ﬁnancial funding.
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